SYBX רווחיות מכירות לפי רווח גולמי Synlogic, Inc.

Synlogic, Inc. (SYBX) seeks to monetize its intellectual assets through licensing and the sale of its developments. The company creates synthetic bacteria to combat gut toxins associated with rare metabolic disorders. Currently, the business is searching for a strategic partner to preserve liquidity following a restructuring. The gross margin level on this GURU.Markets chart is 0.00, which reflects the current level of the metric.
פילוחים אנליטיים ודוחות נתונים של חברת Synlogic, Inc. (SYBX)

For Synlogic, Inc. (SYBX), the efficiency of intellectual property monetization and payments from pharma behemoths directly reflects the company's ability to control direct costs. An analysis of historical gross margins allows for an assessment of the revenue share free of cost of goods sold, where sharp peaks may indicate operational overheating, creating risks for long-term capital stability and share value.